Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer

Heather Hampel, MS, CGC; Rachel Pearlman, MS, CGC; Mallory Beightol, BS, MB(ASCP); Weiqiang Zhao, MD, PhD; Daniel Jones, MD, PhD; Wendy L. Frankel, MD, PhD; Paul J. Goodfellow, PhD; Ahmet Yilmaz, PhD; Kristin Miller, BS; Jason Bacher, BA; Angela Jacobson, MS, CGC; Electra Paskett, PhD; Peter G. Shields, MD; Richard M. Goldberg, MD; Albert de la Chapelle, MD, PhD; Brian H. Shirts, MD, PhD; Colin C. Pritchard, MD, PhD; for the Ohio Colorectal Cancer Prevention Initiative Study Group

IMPORTANCE Universal tumor screening for Lynch syndrome (LS) in colorectal cancer (CRC) is recommended and involves up to 6 sequential tests. Somatic gene testing is performed on stage IV CRCs for treatment determination. The diagnostic workup for patients with CRC could be simplified and improved using a single up-front tumor next-generation sequencing test if it has higher sensitivity and specificity than the current screening protocol.

OBJECTIVE To determine whether up-front tumor sequencing (TS) could replace the current multiple sequential test approach for universal tumor screening for LS.

DESIGN, SETTING, AND PARTICIPANTS Tumor DNA from 419 consecutive CRC cases undergoing standard universal tumor screening and germline genetic testing when indicated as part of the multicenter, population-based Ohio Colorectal Cancer Prevention Initiative from October 2015 through February 2016 (the prospective cohort) and 46 patients with CRC known to have LS due to a germline mutation in a mismatch repair gene from January 2013 through September 2015 (the validation cohort) underwent blinded TS.

MAIN OUTCOMES AND MEASURES Sensitivity of TS compared with microsatellite instability (MSI) testing and immunohistochemical (IHC) staining for the detection of LS.

RESULTS In the 465 patients, mean age at diagnosis was 59.9 years (range, 20-96 years), and 241 (51.8%) were female. Tumor sequencing identified all 46 known LS cases from the validation cohort and an additional 12 LS cases from the 419-member prospective cohort. Testing with MSI or IHC, followed by BRAF p.V600E testing missed 5 and 6 cases of LS, respectively. Tumor sequencing alone had better sensitivity (100%; 95% CI, 93.8%-100%) than IHC plus BRAF (89.7%; 95% CI, 78.8%-96.1%; P = .04) and MSI plus BRAF (91.4%; 95% CI, 81.0%-97.1%; P = .07). Tumor sequencing had equal specificity (95.3%; 95% CI, 92.6%-97.2%) to IHC plus BRAF (94.6%; 95% CI, 91.9%-96.6%; P > .99) and MSI plus BRAF (94.8%; 95% CI, 92.2%-96.8%; P = .88). Tumor sequencing identified 284 cases with KRAS, NRAS, or BRAF mutations that could affect therapy for stage IV CRC, avoiding another test. Finally, TS identified 8 patients with germline DPYD mutations that confer toxicity to fluorouracil chemotherapy, which could also be useful for treatment selection.

CONCLUSIONS AND RELEVANCE Up-front TS in CRC is simpler and has superior sensitivity to current multitest approaches to LS screening, while simultaneously providing critical information for treatment selection.

Published online March 29, 2018. Corrected on May 10, 2018.
Lynch syndrome (LS) affects approximately 3% of all patients with colorectal cancer (CRC), making it the most common hereditary syndrome that predisposes individuals to develop CRC. Individuals with LS are also at increased risk to develop endometrial, ovarian, gastric, and other cancers. Identifying LS in patients with CRC and their at-risk relatives allows them to benefit from intensive cancer surveillance, chemoprevention, and risk-reducing surgical procedures.

Universal tumor screening for LS is recommended for all patients with CRC at diagnosis, and there are several approaches currently used. Initial screening in tumor tissue can begin with immunohistochemical (IHC) staining for the presence of the mismatch repair (MMR) proteins (MLH1, MSH2, MSH6, PMS2) and/or microsatellite instability (MSI) analysis. If the tumor is MSI-high and/or has any absent MMR protein, the tumor is considered to have defective mismatch repair (dMMR). The majority of dMMR CRCs (70%) have absence of the MLH1 and PMS2 proteins associated with sporadic MLH1 promoter methylation. Therefore, if the MLH1 protein is absent or if the tumor is MSI-high, analysis for methylation of the MLH1 promoter and/or testing for its surrogate, the somatic BRAF p.V600E mutation, which is found in 69% of methylated cases, is performed. If either of these tests have positive results, LS is excluded or highly unlikely. False-negative results are a limitation of universal tumor screening; IHC sensitivity is 83% for MLH1, MSH2, or MSH6 mutations, and MSI sensitivity is 87% for MLH1 or MSH2 mutations and 77% for MSH6 mutations. Traditional sequential testing is complex and confusing to patients and clinicians and occurs over a prolonged period, incurring risk for loss to follow-up.

Germline DNA testing of the MMR genes is performed for patients with dMMR without MLH1 promoter methylation, and a diagnosis of LS is confirmed by the presence of a germline mutation. However, only 25% to 67% of patients with a dMMR CRC are found to have a germline mutation in an MMR gene. In the past, when a germline mutation was not found, patients were left with unexplained MMR deficiency and typically treated as if they had LS without a detectable germline mutation. However, up to 68% of nonmethylated dMMR cases without a germline MMR mutation have acquired 2 somatic mutations in the MMR gene corresponding to the protein absence on IHC, resulting in dMMR in the tumor. These “double somatic” patients and their relatives do not have LS and do not need to follow the intensive LS cancer surveillance recommendations.

In addition to identifying patients more likely to have LS, universal tumor screening identifies patients with MSI-high tumors who may respond well to US Food and Drug Administr-
For treatment purposes, the National Comprehensive Cancer Network guidelines recommend that stage IV CRC tumors undergo targeted mutation testing of the KRAS, NRAS, and BRAF genes to help guide treatment.  

While it is known that tumor sequencing (TS) can be used to determine the MSI status of tumors, it is not known whether it can be used more specifically to identify patients with LS. The primary objective of this study was to compare the performance of up-front TS (Figure 2) with the current universal tumor screening for LS approaches (Figure 1). The secondary aim of this study was to evaluate TS for detection of other variants that might alter cancer therapy.

Methods

Participants

The Ohio Colorectal Cancer Prevention Initiative (OCCPI) was created with the aim of decreasing CRC incidence in Ohio by identifying patients with hereditary predisposition, increasing colonoscopy adherence for first-degree relatives of patients with CRC, and encouraging future research through the creation of a biorepository. Patients were enrolled at 51 participating Ohio hospitals. Institutional review board approval was obtained by the individual hospitals, community oncology programs, or by ceding review to the Ohio State University Institutional Review Board. Written informed consent was obtained.

All CRC cases (n = 419) undergoing testing as part of the OCCPI study between October 2015 and February 2016 were chosen for this project. Cases were coded so all individuals involved in the TS diagnostic process were blinded to previous tumor screening and germline test results. An additional validation set of 46 cases known to have germline MMR gene mutations were coded and mixed with the initial set to ensure that there were enough mutation-positive cases to test the performance of TS in the identification of germline MMR mutations. These 46 cases included all germline MMR gene mutation carriers identified from January 2013 through September 2015 in the OCCPI study for which there was leftover tumor DNA after all prior standard tests had been completed (MSI and, when necessary, MLH1 methylation). The demographic characteristics of these 465 patients are presented in Table 1.

Traditional Universal Tumor Screening

The standard universal tumor screening tests and germline mutation testing panels used in the OCCPI study have been described. Microsatellite instability testing was completed using the Promega MSI Analysis System with instability in at least 2 of 5 markers required for MSI-high and instability in 1 of 5 markers considered MSI-low. Immunohistochemistry for the MMR proteins was performed either (1) by the hospital that performed the original pathology review using all 4 MMR stains or (2) by the central study pathologist (W.L.F.) using the 2-stain method as previously described to reduce IHC costs. Staining for all 4 MMR proteins was undertaken if MSI analysis could not be performed or if the MSI and IHC results were discordant. Mismatch repair proteins staining more than 5% of cancer cells were considered “present”; 1% to 5% staining was “equivocal” and we deferred to the MSI result to determine whether germline genetic testing was necessary; and less than 1% was considered “absent.” MLH1 promoter methylation was assessed at 4 CpG sites between −209 and −188 using pyrosequencing when tumors were MSI-high and/or absent MLH1 and PMS2 proteins on IHC. The mean percent of methylation detected at the 4 CpG sites was used to classify tumors as methylated (≥10%) or unmethylated (<10%).

A total of 197 of the 419 prospective cases underwent germline genetic testing. In accordance with current practice, any patients with CRC found to have a dMMR tumor (MSI-high and/or IHC showing lack of expression of ≥1 MMR protein) without MLH1 promoter methylation underwent germline genetic testing (n = 26). In addition, as part of the OCCPI research study, any patient with CRC with a MMR proficient tumor who received a diagnosis before age 50 years (n = 75), had a first-degree relative with CRC or endometrial cancer (n = 82), or had synchronous or metachronous CRC or endometrial cancer tumors underwent germline genetic testing (n = 19). Germline genetic testing for this study included a next-
generation sequencing (NGS) panel of cancer susceptibility genes including all of the LS genes as described previously.\textsuperscript{24}

Tumor Next-Generation Sequencing
Tumor sequencing was performed using University of Washington (UW)-OncoPlex in the Clinical Laboratory Improvement Amendments–certified laboratory setting (http://web.labmed.washington.edu/tests/genetics/UW-OncoPlex) as previously described.\textsuperscript{19,27} UW-OncoPlex is a clinically validated targeted NGS deep sequencing panel that sequences to 500 × mean depth all exons, introns, and flanking regions of MLH1, MSH2, and MSH6, and all exons of PMS2 in addition to assessing BRAF, KRAS, NRAS, and MSI status among other genes (full description of test in the eAppendix in Supplement 1).\textsuperscript{19} Analysis and interpretation of sequencing results was performed by an expert molecular pathologist (C.C.P.) who was blinded to all clinical and molecular data, and a second pass was performed by an independent molecular pathologist (B.H.S.).

Analysis
The definition of a positive screening test result in the current screening pathway is any case that was MSI-high and/or had abnormal IHC with negative BRAF V600E test results. The definition of a positive screening test result in the proposed TS pathway is any case that had mutations identified in at least 1 of the MMR genes at a variant allele fraction that was consistent with the possibility of a germline mutation with MSI and BRAF V600E status taken into account. A true positive result was any case with a germline MMR gene mutation confirmed by germline genetic testing. False-positive results included double somatic MMR mutation cases and methylated cases that were missed with BRAF testing. Sensitivity and specificity were calculated using standard methods on the combined results from all completed tests in both the prospective and validation cohorts. Positive predictive values (PPVs) and negative predictive values (NPVs) were calculated using population prevalence from the prospective cohort only because an accurate prevalence in the tested population is important for this calculation. Statistical comparisons of sensitivity and specificity results were performed in R using the McNemar test (mcnemar.test function) with continuity correction.

Results
Complete data for all 465 cases from this study can be found in the eWorksheet in Supplement 2.

Microsatellite Instability
Using the Promega polymerase chain reaction (PCR) panel, MSI-high was detected in 76 of 419 (18.1%) of the unselected CRC cases undergoing standard tumor screening for LS. All 76 tumors were also found to be MSI-high based on MSI testing by the mSINGS method with TS (sensitivity, 100%; 95% CI, 95.3%-100%).\textsuperscript{26} Among the 341 tumors classified as microsatellite stable (MSS) or MSI-low using PCR-based MSI analysis, TS findings were concordant for 340 cases (specificity, 99.7%; 95% CI, 98.4%-100%). The 1 discrepant tumor was classified as MSS by the PCR panel and MSI-high by TS. Another case was classified as MSI-low by the PCR panel but MSS by TS; this was considered concordant because MSI-low cases are treated like MSS cases for the purposes of LS screening. Two tumors that were classified as MSS by the PCR panel failed MSI testing by TS due to low DNA quality. The PPV of TS to determine MSI was 98.7% (95% CI, 91.5%-99.8%) and the NPV was 100%. This compares favorably to the ability of IHC to detect MSI-high cases (Table 2).

MLH1 Promoter Methylation
On the basis of pyrosequencing, 50 of 76 (66%) of MSI-high cases were MLH1 methylated and 26 of 76 (34%) were unmethylated. Tumor sequencing used the included BRAF V600E mutation as a surrogate for MLH1 methylation in MSI-high tumors.\textsuperscript{12,28} Because approximately 68% of tumors with MLH1 methylation have the BRAF V600E mutation, some methylated cases will be missed using this approach.\textsuperscript{27} In this manner, TS correctly identified 42 of 50 (84% sensitivity) tumors with MLH1 promoter methylation and 26 of 26 MSI-high tumors without MLH1 methylation (100% specificity). The PPV was 100%, and the NPV was 63.6%.

Table 1. Demographic Characteristics of 465 Patients With Colorectal Cancer (CRC)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value (N = 465)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at CRC diagnosis, mean (range), y</td>
<td>59.9 (20-96)</td>
</tr>
<tr>
<td>Age at diagnosis, No. (%), y</td>
<td></td>
</tr>
<tr>
<td>&lt;50</td>
<td>104 (22.4)</td>
</tr>
<tr>
<td>≥50</td>
<td>361 (78.6)</td>
</tr>
<tr>
<td>CRC site, No. (%)</td>
<td></td>
</tr>
<tr>
<td>Right colon</td>
<td>184 (39.6)</td>
</tr>
<tr>
<td>Left colon</td>
<td>148 (31.8)</td>
</tr>
<tr>
<td>Transverse colon</td>
<td>35 (7.5)</td>
</tr>
<tr>
<td>Rectum</td>
<td>86 (18.5)</td>
</tr>
<tr>
<td>Not specified</td>
<td>12 (2.6)</td>
</tr>
<tr>
<td>Pathologic stage, No. (%)</td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>84 (18.1)</td>
</tr>
<tr>
<td>II</td>
<td>122 (26.2)</td>
</tr>
<tr>
<td>III</td>
<td>184 (39.6)</td>
</tr>
<tr>
<td>IV</td>
<td>29 (6.2)</td>
</tr>
<tr>
<td>Unknown</td>
<td>46 (9.9)</td>
</tr>
<tr>
<td>Sex, No. (%)</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>224 (48.2)</td>
</tr>
<tr>
<td>Female</td>
<td>241 (51.8)</td>
</tr>
<tr>
<td>Self-reported race, No. (%)</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>414 (89.0)</td>
</tr>
<tr>
<td>African American or black</td>
<td>38 (8.2)</td>
</tr>
<tr>
<td>Asian</td>
<td>4 (0.9)</td>
</tr>
<tr>
<td>Other</td>
<td>9 (1.9)</td>
</tr>
<tr>
<td>Hispanic, No. (%)</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>5 (1.1)</td>
</tr>
<tr>
<td>No</td>
<td>460 (98.9)</td>
</tr>
</tbody>
</table>
LS Germline Gene Mutations

Twelve patients were found to have LS (eTable 1 in Supplement 1) (2 MLH1, 5 MSH2, 1 MSH6, 4 PMS2) in the prospective group, and TS correctly identified all 12 (100%). Current screening methods would have missed 1 patient with a PMS2 mutation (8%) because although the tumor had absent MLH1 and PMS2 proteins and was MSI-high, the MLH1 promoter was methylated. As a result, this case would have been considered a sporadic tumor and no genetic counseling or testing would have been recommended.

Validation Set of Germline MMR Gene Mutations

Tumor DNA samples from 46 patients known to have pathogenic germline mutations in MMR genes were analyzed along with the prospective cases (eTable 1 in Supplement 1) (11 MLH1, 20 MSH2, 6 MSH6, 9 PMS2). Tumor sequencing correctly identified 46 of 46 (100%) pathogenic germline MMR gene mutations in this validation set.

Comparison of TS With MSI and IHC

The diagnostic performance of the TS, MSI, and IHC assays to predict MMR gene mutations was evaluated in both cohorts combined (Table 2) (n = 464 for MSI and IHC and n = 439 for TS omitting 25 cases that failed TS due to low tumor DNA quality or quantity). One dMMR tumor (MSI-high, IHC absent MSH2 and MSH6) was removed from analysis because it had no germline mutation and no evidence of double somatic MMR gene mutations, so it was unclear whether to count this case as a true- or false-positive result.

Overall, TS (which includes Braf testing) successfully identified all LS cases (58 of 58), whereas MSI followed by Braf testing failed to identify 3 cases of LS and IHC followed by Braf testing failed to identify 6 cases of LS. Three hundred sixty-three cases had a negative screening test result and 76 cases had a positive screening test result based on TS. Of the 76 cases with a positive screening test result, 58 had LS and 18 were considered false-positive results (including 9 cases with double somatic MMR mutations and 9 with MLH1 methylation). Therefore, the sensitivity of TS for the detection of LS was 100% (95% CI, 93.8%-100%) and specificity was 95.3% (95% CI, 92.6%-97.2%). The PPV and NPV for all of the LS screening tests were calculated using only the prospective cohort because disease prevalence can affect these measures. The PPV of TS was 40% (12 of 30; 95% CI, 29.8%-51.1%) and NPV was 100% (363 of 363; 95% CI, 99.1%-100%).

For comparison in the same cohort, the sensitivity of MSI followed by Braf testing for the detection of LS was 91.4% (95% CI, 81.0%-97.1%) and specificity was 94.8% (95% CI, 92.2%-96.8%). The PPV was 34.4% (11 of 32; 95% CI, 25.0%-45.1%) and NPV was 99.7% (385 of 386; 95% CI, 98.3%-100%). The sensitivity of IHC followed by Braf testing for the detection of LS was 89.7% (95% CI, 78.8%-96.1%) and the specificity was 94.6% (95% CI, 91.9%-96.6%). The PPV was 33.3% (11 of 33; 95% CI, 24.3%-43.7%) and NPV was 99.7% (383 of 384; 95% CI, 98.3%-100%).

The sensitivity of TS (which includes Braf testing) was significantly higher than the sensitivity of IHC followed by Braf (P = .04) and was higher (but not statistically significantly) than the sensitivity of MSI followed by Braf (P = .07). Tumor sequencing also had slightly better specificity (95.3%; 95% CI, 92.6%-97.2%) than IHC plus Braf testing (94.6%) and MSI plus Braf testing (94.8%).

Germline and Somatic Mutations With Potential to Affect Treatment

Tumor sequencing as the sole molecular test for CRC must include testing both to aid in LS detection and for standard-of-care treatment purposes. Current National Comprehensive Cancer Network guidelines (v2.2017) recommend tumor Kras, NRAS, and Braf testing in all stage IV CRC. While only 6.2% of this cohort had stage IV disease, generally approximately 25% of CRCs are diagnosed at stage IV and require this testing. In addition, many patients with earlier-stage disease will progress to stage IV, at which time they could benefit from having this information from their primary tumor. In total, 380 of the 465 (81.7%) CRC tumors had at least 1 somatic mutation that could have therapeutic implications; 283 cases had either a Kras (n = 190), Nras (n = 22), or Braf (n = 71) mutation. In addition, 8 patients (8 of 465 [1.7%]) were found to have known pathogenic germline mutations in DPYD, placing them at risk for severe reactions to fluorouracil.
chemotherapy.\textsuperscript{30,31} Having this knowledge at the time of diagnosis could prevent severe, potentially life-threatening adverse reactions to fluorouracil in these patients.

Discussion

Here we show that up-front TS could effectively replace all current standard-of-care tests performed on CRC tumors, including those used for universal tumor screening for LS and those used for treatment purposes, as long as there is enough tumor available for this testing. The sensitivity of TS for LS screening is superior to the current standard-of-care approach, while simultaneously providing additional data that may be useful in guiding treatment. Tumor sequencing can also simplify the complex and time-consuming multistep algorithm to screen for LS (Figures 1 and 2).

Limitations

While unlikely, it is possible that some cases of LS were missed by both the reference standard and index tests in this study, which would result in an overestimate of the sensitivity and specificity of all tests.

A limitation of TS is that it has not been optimized to detect all possible germline mutations. For example, it is unlikely that TS would be able to detect mutations in the pseudogene region (exons 12-15) of \textit{PMS2} for which mutation detection is particularly challenging.\textsuperscript{23} While TS may not be able to detect all large rearrangements in cancer susceptibility genes including \textit{EPCAM} deletions,\textsuperscript{15} it did detect 10 large deletions in this cohort. Cases like these would presumably be MSI-high without a \textit{BRAF} mutation, which would be suspicious for LS even if no somatic MMR gene mutations were identified and the patient should still be referred for cancer genetic testing. Like MSI and IHC, TS is only a screening test. Some patients with normal TS results would still need to be referred to cancer genetics if their personal and/or family history of cancer is concerning for a possible hereditary cancer syndrome. In addition, all patients found to have putative germline mutations on TS will need to confirm the mutation with germline sequencing; however, this may be done using the less expensive single-mutation test rather than a full gene sequence or NGS panel. It should be noted that an advantage of TS is the ability to help identify double somatic MMR mutations as were found in 14 of 419 (3.3%) of the prospective cohort. These patients would have had to have TS testing after having MSI or IHC, \textit{BRAF}, or \textit{MLH1} methylation testing and germline sequencing because their dMMR tumor would have been left unexplained when no germline mutation was found.

Another limitation to implementing TS as a single molecular test for all patients with CRC is the possibility of a longer turnaround time compared with MSI or IHC; however, the turnaround time for TS is currently a median of 2 weeks and it requires less time overall by eliminating multiple follow-up tests in a subset of cases. Up-front TS may also create the need for new workflows as some hospitals will need to shift to using reference laboratories instead of performing tests locally; however, it should ultimately streamline the molecular workup of CRC. Another barrier for TS is insufficient or poor-quality DNA from formalin-fixed paraffin-embedded tissue (5.4% in this series). It is possible that we could have salvaged some of these cases by getting recuts from the blocks. Insufficient tumor DNA is a known problem for MSI testing as well, with 14.2% (474 of 3346) of CRC cases having insufficient tumor to perform MSI testing in the OCCPI study and these would also have been insufficient for TS. Immunohistochemistry could be used as a backup test for cases with insufficient tumor material for MSI or TS because it requires far less material. Ultimately, the use of 1 test requiring tumor for TS instead of potentially more than 4 tests requiring tumor will leave more tissue available for clinical trials or other needs. Finally, cost-effectiveness will need to be considered; however, it is anticipated that the costs of TS will decrease substantially as has been seen for germline NGS.

Tumor sequencing could also be optimized to search for putative germline mutations in other cancer susceptibility genes. While this was not the aim of the present study, we did identify 36 additional cases with potential germline mutations in other cancer susceptibility genes. Seventeen of these cases had germline NGS as part of the OCCPI study and 8 of these mutations (47%) were confirmed to be present in the germline (eTable 2 in Supplement 1).

Conclusions

In summary, our data support that up-front TS is both simpler and analytically superior to current LS screening tests and could replace all current molecular testing for patients with CRC.
Obtained funding: Hampel, Paskett, Shields, Goldberg, de la Chapelle.

Administrative, technical, or material support: Hampel, Pearlman, Beightol, Zhao, Jones, Frankel, Miller, Bacher, Jacobson, Shields, Goldberg, de la Chapelle, Pritchard.

Study supervision: Hampel, Pearlman, Jones, Paskett, Goldberg, de la Chapelle, Pritchard.

Conflict of Interest Disclosures: Ms Hampel discloses a consulting or advising role with Invitae and Genomyx Medical, and stock in Genome Medical. Dr Paskett has a research grant (to the institution) from Merck Foundation and stock in Pfizer. Dr de la Chapelle discloses a patent or intellectual property interest with Genzyme and Ipsogen. No other disclosures are reported.

Funding/Support: The Ohio Colorectal Cancer Prevention Initiative (OCCPI) is supported by a grant from Pelotonia, an annual cycling event in Columbus, Ohio, that supports cancer research at the Ohio State University Comprehensive Cancer Center—James Cancer Hospital and Solove Research Institute. This study was also supported in part by the National Institute (grant P30CA16058). Myriad Genetic was donated the germline next-generation sequencing testing for mismatch repair-deficient patients for this study.

Role of the Funder/Sponsor: The funding sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Group Information: The Ohio Colorectal Cancer Prevention Initiative study group includes: Adena Regional Medical Center, Chillicothe, Ohio: Linda Kight, BSN, Jeffrey Vandeusen, MD, PhD; Akron General Medical Center, Akron, Ohio: Cathy Farmer, OCN, Esther Rehms, MD, Debbie Thomas, MSN; Atrium Medical Center, Middletown, Ohio: Sandy Fletcher, BSN, Albert Malcolm, MD; Aultman Hospital, Canton, Ohio: Kathleen Collins, BSN, Kristin Shine, BSN, Janet Moore, BSN, Lisa Weeman, MD; Blanchard Valley Health System, Findlay, Ohio: Sharon Cole, RN, Brianne Hottinger, BSN, Shannon Kohls, RN; Children’s Hospital Medical Center, Akron, Ohio: Julie D’Attonio, RN, Marcie Parker, MS, LGG, Jennifer Stein, MS, LGG, Catherine Ward-Melver, MD; Cincinnati Oncology Hematology Care—Mercy West, Mercy Fitzgerald, Mercy Anderson, Mercy Clermont, Jewish Hospital, Cincinnati, Ohio: Dawn Asbhire, BSN, Kim Brockman, RN, Sheena Chandler, RN, Nicole Given, BS, Brittany Hagen, BS, Lynnette Hart, BS, Alesha Hubbard, BSN, Kimmy Miller, BSN, Lisa Schmid, BSN, Lindsay Vogel, BS; Cleveland Clinic—main campus, Hillcrest, Fairview, South Pointe, Independence/Strongsville, Cleveland, Ohio: Carla Greenwood, AA, Matthew Kalady, MD, Timothy W. Sopp, MD, Cathy Huegny, RN, Herman Kessler, MD, PhD, Samantha Kopack, Brandie Leach, MS, LGG, Jessica Marquardt, MD, LGG, Kimberly McDonald, PhD, Patti O’Reilly, Michelle Parson, BSN, Thomas Plesic, MD, Cathy Schiero, BSN, Kathy Smolenski, BSN, Traci Stafford, RN; Columbus, OH: Colin C. Pritchard, MD, PhD, Peter Stanich, MD, Benjamin Swanson, MD, Colin C. Pritchard, MD, PhD, Brian H. Shirts, MD, PhD, Upper Valley Medical Center, Troy, Ohio: Heather Penwell, BS, Rajeev Kulkarni, MD; Wayne Healthcare, Greenhville, Ohio: Cathrine Jill Brown, BS, Manish Sheth, MD; Wright-Patterson Medical Center, Dayton, Ohio: Joyce Russo, RN, Roger Wood, MD.

Additional Information: In addition to the eWorksheet in Supplement 2, complete data for all 465 cases from this study can be found at https://cancer.osu.edu/research-and-education/pelotonia-funded-research/statewide-colon-cancer-initiative.

REFERENCES
Assessment of Tumor Sequencing to Screen for Lynch Syndrome in Colorectal Cancer


